Please note, these are the actual video- recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. Select slides from the original presentation are omitted where Research To Practice was unable to obtain permission from the publication source and/or author. Links to view the actual reference materials have been provided for your use in place of any omitted slides.
19
Embed
Biology of EGFR Mutations and Acquired Resistance to EGFR TKIs
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw,
unedited content. Select slides from the original presentation are omitted where Research To
Practice was unable to obtain permission from the publication source and/or author. Links to view the actual reference materials have been provided for
your use in place of any omitted slides.
Biology of EGFR Mutations and Acquired Resistance to EGFR
TKIs
Thomas J. Lynch, Jr., M.D.
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital
Cancer Paradigm 2011
Epidermal Growth Factor Receptor Mutations
Study design
Gefitinib(250 mg / day)
Carboplatin (AUC 5 or 6) /
paclitaxel (200 mg / m2)
q 3 weeks#
1:1 randomisation
*Never smokers, <100 cigarettes in lifetime; light ex-smokers, stopped 15 years ago and smoked 10 pack years; #limited to a maximum of 6 cycles Carboplatin / paclitaxel was offered to gefitinib patients upon progressionPS, performance status; EGFR, epidermal growth factor receptor
Patients• Chemonaïve• Age ≥18 years • Adenocarcinoma histology